Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1

Cancer Gene Therapy

Volumn 18, Issue 10, 2011, Pages 685-694

  Wood, L W ^a   Shillitoe, E J ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

breast cancer; caspase inhibitor; HSV 1; oncolytic virus

Indexed keywords

CASPASE INHIBITOR; N BENZYLOXYCARBONYLVALINE ALANINE ASPARTIC ACID FLUOROMETHYLKETONE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL GROWTH; DRUG ACTIVITY; GROWTH INHIBITION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS REPLICATION;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; ENZYME INHIBITORS; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VERO CELLS; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 80052969634     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.34     Document Type: Article

References (41)

1. Griffith C, Noonan S, Lou E, Shillitoe EJ. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther 2007; 14: 985-993. (Pubitemid 350115356)
2. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006; 66: 637-646. (Pubitemid 44436713)
3. Israyelyan AH, Melancon JM, Lomax LG, Sehgal I, Leuschner C, Kearney MT et al. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. Hum Gene Ther 2007; 18: 457-473. (Pubitemid 46850137)
4. Brandt CR. The role of viral and host genes in corneal infection with herpes simplex virus type 1. Exp Eye Res 2005; 80: 607-621. (Pubitemid 40602961)
5. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10: 292-303. (Pubitemid 36305598)
6. Mehta H, Muller J, Markovitz NS. Ultrastructural analysis of ICP34.5-herpes simplex virus 1 replication in mouse brain cells in vivo. J Virol 2010; 84: 10982-10990.
7. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 2177-2185. (Pubitemid 28498004)
8. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replicationcompetent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162-169.
9. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966. (Pubitemid 24258091)
10. Kaufman HL, Bines SD. OPTIM trial: a phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6: 941-949.
11. Yao F, Murakami N, Bleiziffer O, Zhang P, Akhrameyeva NV, Xu X et al. Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. J Virol 2010; 84: 8163-8171.
12. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 1999; 13: 1325-1334. (Pubitemid 29382501)
13. Manservigi R, Argnani R, Marconi P. HSV recombinant vectors for gene therapy. Open Virol J 2010; 4: 123-156.
14. Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005-4015.
15. Cinatl Jr J, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel JU et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 2003; 63: 1508-1514. (Pubitemid 36373636)
16. Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res 2008; 14: 1519-1528. (Pubitemid 351413937)
17. Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, Lin SF et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg 2010; 97: 1385-1394.
18. Lou E, Kellman R, Shillitoe E. Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol 2002; 38: 349-356. (Pubitemid 34655689)
19. Aubert M, Pomeranz LE, Blaho JA. Herpes simplex virus blocks apoptosis by precluding mitochondrial cytochrome c release independent of caspase activation in infected human epithelial cells. Apoptosis 2007; 12: 19-35. (Pubitemid 46009501)
20. Aubert M, Blaho JA. Viral oncoapoptosis of human tumor cells. Gene Ther 2003; 10: 1437-1445. (Pubitemid 36987137)
21. Kraft RM, Nguyen ML, Yang X-H, Thor AD, Blaho JA. Caspase 3 activation during herpes simplex virus 1 infection. Virus Res 2006; 120: 163-175. (Pubitemid 43947312)
22. Nguyen ML, Kraft RM, Blaho JA. Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis. J Gen Virol 2007; 88: 1866-1875. (Pubitemid 47009927)
23. Sanfilippo CM, Chirimuuta FN, Blaho JA. Herpes simplex virus type 1 immediate-early gene expression is required for the induction of apoptosis in human opethelial HEp-2 cells. J Virol 2004; 78: 224-239. (Pubitemid 37549735)
24. Langelier Y, Bergeron S, Chabaud S, Lippens J, Guilbault C, Sasseville AM-J et al. The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. J Gen Virol 2002; 83: 2779-2789. (Pubitemid 35276978)
25. Leopardi R, Van Sant C, Roizman B. The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc Natl Acad Sci USA 1997; 94: 7891-7896.
26. Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, Gonen M, Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 2004; 10: 3225-3232. (Pubitemid 38619704)
27. Heinrich A, Balszuweit F, Thiermann H, Kehe K. Rapid simultaneous determination of apoptosis, necrosis, and viability in sulfur mustard exposed HaCaT cell cultures. Toxicol Lett 2009; 191: 260-267.
28. Yang W, Guastella J, Huang JC, Wang Y, Zhang L, Xue D et al. MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity. Br J Pharmacol 2003; 140: 402-412. (Pubitemid 37249201)
29. Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006; 2006: pe44.
30. Gibson SA, Pellenz C, Hutchison RE, Davey FR, Shillitoe EJ. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 2000; 6: 213-222. (Pubitemid 30064996)
31. Bennett J, Adsumilli P, Petrowsky H, Burt B, Roberts G, Delman K. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004; 18: 1001-1003. (Pubitemid 39561505)
32. Jiang C, Komazin-Meredith G, Tian W, Coen DM, Hwang CB. Mutations that increase DNA binding by the processivity factor of herpes simplex virus affect virus production and DNA replication fidelity. J Virol 2009; 83: 7573-7580.
33. Teixeira C, Reed JC, Pratt MA. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-3907.
34. Cunningham AR, Cunningham SL, Day BW. Identification of structural components associated with cytostatic activity in MCF-7 but not in MDA-MB-231 cells. Bioorg Med Chem 2003; 11: 5249-5258. (Pubitemid 37353012)
35. Chung R, Saeki Y, Chiocca E. B-myb promoter retargeting of herpes simplex virus gamma-34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 1999; 73: 7556-7564. (Pubitemid 29383239)
36. Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ. The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med 1997; 3: 333-337. (Pubitemid 27112933)
37. White E. Autophagic cell death unraveled: pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy 2008; 4: 399-401. (Pubitemid 351705133)
38. Iwata A, Harlan JM, Vedder NB, Winn RK. The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. Blood 2002; 100: 2077-2080. (Pubitemid 35001240)
39. Felderhoff-Mueser U, Sifringer M, Pesditschek S, Kuckuck H, Moysich A, Bittigau P et al. Pathways leading to apoptotic neurodegeneration following trauma to the developing rat brain. Neurobiol Dis 2002; 11: 231-245. (Pubitemid 36135688)
40. Sangeetha VM, Kale VP, Limaye LS. Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse. PLoS One 2010; 5: e12221.
41. Emamaullee JA, Stanton L, Schur C, Shapiro AM. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 2007; 56: 1289-1298. (Pubitemid 46715609)